ATE83663T1 - Imipramin enthaltende arzneizubereitungen. - Google Patents

Imipramin enthaltende arzneizubereitungen.

Info

Publication number
ATE83663T1
ATE83663T1 AT90401370T AT90401370T ATE83663T1 AT E83663 T1 ATE83663 T1 AT E83663T1 AT 90401370 T AT90401370 T AT 90401370T AT 90401370 T AT90401370 T AT 90401370T AT E83663 T1 ATE83663 T1 AT E83663T1
Authority
AT
Austria
Prior art keywords
pct
pharmaceutical preparations
preparations containing
imipramine
date nov
Prior art date
Application number
AT90401370T
Other languages
German (de)
English (en)
Inventor
Anne Coutel-Egros
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Application granted granted Critical
Publication of ATE83663T1 publication Critical patent/ATE83663T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT90401370T 1989-05-24 1990-05-22 Imipramin enthaltende arzneizubereitungen. ATE83663T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (1)

Publication Number Publication Date
ATE83663T1 true ATE83663T1 (de) 1993-01-15

Family

ID=9381955

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90401370T ATE83663T1 (de) 1989-05-24 1990-05-22 Imipramin enthaltende arzneizubereitungen.
AT90401369T ATE98867T1 (de) 1989-05-24 1990-05-22 Poroese einheitsform und verfahren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT90401369T ATE98867T1 (de) 1989-05-24 1990-05-22 Poroese einheitsform und verfahren.

Country Status (24)

Country Link
US (1) US5244881A (en:Method)
EP (2) EP0399902B1 (en:Method)
JP (1) JP2948271B2 (en:Method)
KR (1) KR0163423B1 (en:Method)
AT (2) ATE83663T1 (en:Method)
AU (2) AU623779B2 (en:Method)
CA (2) CA2017360A1 (en:Method)
DD (1) DD297915A5 (en:Method)
DE (2) DE69000641T2 (en:Method)
DK (2) DK0399902T3 (en:Method)
ES (2) ES2062437T3 (en:Method)
FI (1) FI103712B1 (en:Method)
FR (1) FR2647343B1 (en:Method)
GR (1) GR3006655T3 (en:Method)
IE (2) IE64370B1 (en:Method)
IL (2) IL94460A0 (en:Method)
NO (1) NO180517C (en:Method)
NZ (2) NZ233766A (en:Method)
PL (1) PL285327A1 (en:Method)
PT (2) PT94139B (en:Method)
TW (1) TW257672B (en:Method)
WO (1) WO1990014089A1 (en:Method)
YU (1) YU100790A (en:Method)
ZA (2) ZA903895B (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196426T1 (de) * 1991-06-21 2000-10-15 Takeda Chemical Industries Ltd Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
KR100256147B1 (ko) 1991-12-24 2000-08-01 오노다 마사요시 구강내 붕해성 제제 및 이의 제조방법
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
EP0760680A1 (en) * 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
DE69840495D1 (de) * 1997-02-20 2009-03-12 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
AU753519B2 (en) * 1998-02-05 2002-10-17 Novartis Ag Compositions containing organic compounds
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
JP4724367B2 (ja) 2002-01-15 2011-07-13 ユセベ ファルシム ソシエテ アノニム 処方
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
BR0307935A (pt) 2002-02-25 2005-03-29 Diffusion Pharmaceuticals Llc Sais de trans carotenóide bipolares e seus usos
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US8030350B2 (en) * 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc USE OF BIPOLAR TRANS-CAROTINOIDES AS PRE-TREATMENT AND TREATMENT OF PERIPHERAL VASCULAR DISEASE
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
WO2009058399A1 (en) 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
AU2009288006B2 (en) * 2008-09-05 2014-07-17 Mcneil-Ppc, Inc. Method for making cetirizine tablets
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
CN103124498A (zh) 2010-06-02 2013-05-29 扩散药品有限公司 双极性反式类胡萝卜素的口服制剂
EP3210597A1 (en) * 2010-09-13 2017-08-30 Bev-RX, Inc. Aqueous drug delivery system comprising off- flavor masking agent
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (en:Method) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
WO1986003198A1 (fr) * 1984-11-27 1986-06-05 Dainippon Pharmaceutical Co., Ltd. Derives de 2-(1-piperazinyle)-4-substitue phenylquinoline, procede de preparation et composition medicinale les contenant
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
IE64370B1 (en) 1995-07-26
DD297915A5 (de) 1992-01-30
AU623779B2 (en) 1992-05-21
NO180517B (no) 1997-01-27
EP0399903B1 (fr) 1992-12-23
IL94459A (en) 1995-01-24
ES2062437T3 (es) 1994-12-16
JPH0356412A (ja) 1991-03-12
AU5582890A (en) 1991-01-10
IL94460A0 (en) 1991-03-10
FR2647343B1 (fr) 1994-05-06
PT94139A (pt) 1991-01-08
ZA903978B (en) 1991-03-27
NO180517C (no) 1997-05-07
FI902553A0 (fi) 1990-05-23
ZA903895B (en) 1991-03-27
NO902280D0 (no) 1990-05-23
IL94459A0 (en) 1991-03-10
NZ233766A (en) 1991-08-27
DE69005359T2 (de) 1994-05-05
DE69000641D1 (de) 1993-02-04
IE63317B1 (en) 1995-04-05
CA2017355A1 (fr) 1990-11-24
KR0163423B1 (ko) 1998-12-01
CA2017360A1 (fr) 1990-11-24
TW257672B (en:Method) 1995-09-21
NZ233784A (en) 1993-04-28
NO902280L (no) 1990-11-26
JP2948271B2 (ja) 1999-09-13
EP0399903A1 (fr) 1990-11-28
DE69005359D1 (de) 1994-02-03
PT94138B (pt) 1996-12-31
KR900017570A (ko) 1990-12-19
EP0399902B1 (fr) 1993-12-22
ES2054289T3 (es) 1994-08-01
YU100790A (en) 1992-05-28
AU5743390A (en) 1990-12-18
PL285327A1 (en) 1991-02-11
IE901821L (en) 1990-11-24
PT94139B (pt) 1996-12-31
US5244881A (en) 1993-09-14
WO1990014089A1 (fr) 1990-11-29
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
FI103712B1 (fi) 1999-08-31
FR2647343A1 (fr) 1990-11-30
DK0399903T3 (da) 1993-02-08
AU631888B2 (en) 1992-12-10
ATE98867T1 (de) 1994-01-15
DE69000641T2 (de) 1993-06-09
IE901862L (en) 1990-11-24
DK0399902T3 (da) 1994-02-14
PT94138A (pt) 1991-01-08
GR3006655T3 (en:Method) 1993-06-30

Similar Documents

Publication Publication Date Title
ATE83663T1 (de) Imipramin enthaltende arzneizubereitungen.
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
IT8821134A0 (it) Frazioni oligomeriche procianidoliche, loro procedimentodi preparazione e composizioni farmaceutiche che le contengono.
DK119785D0 (da) Insulinpraeparat
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
MY101566A (en) Pharmaceutical compositions.
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
Seo Recommendations for the Improvement of the Medical Licensing Examination
IT1216535B (it) O_(1,2_di_0_acetilglicero_3_fosforil)etanolamina, procedimento per la sua preparazione e suo uso terapeutico.
ITMI912550A1 (it) Derivato di mentile, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
MX9200443A (es) Hidrato de 6-ciclohexil-2'-o-metil-adenosina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IT8920755A0 (it) Derivato di idrossiprolina, sua preparazione e composizioni farmaceutiche che lo contengono.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee